Management discusses expert clinical perspectives on CAN-2409 Phase 3 prostate cancer data on a conference call to be held on June 3 at 1 pm. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics Receives FDA RMAT Designation for CAN-2409
- Candel Therapeutics receives FDA RMAT designation to CAN-2409
- Candel Therapeutics to host investor call on CAN-2409 Phase 3 data
- Candel Therapeutics Unveils Promising Phase 3 Trial Results
- Promising Pipeline Developments and Strong Data Support Buy Rating for Candel Therapeutics